评估系统药理学模型与评估标准药代动力学-药效学模型不同。
Evaluating systems pharmacology models is different from evaluating standard pharmacokinetic-pharmacodynamic models.
机构信息
MedImmune LLC, Clinical Pharmacology, Drug Metabolism, and Pharmacokinetics, Cambridge, UK.
出版信息
CPT Pharmacometrics Syst Pharmacol. 2014 Feb 19;3(2):e101. doi: 10.1038/psp.2013.77.
Abstract
Based on the author's recent experience, there appears to be some confusion regarding the steps required to qualify a systems pharmacology model as adequate for the intended purpose. This manuscript outlines the model evaluation approach used in the author's recent publication(1) on the systems pharmacology of a 5-lipoxygenase inhibitor and is an attempt to generate discussion on this topic within the pharmacometrics and systems pharmacology community.
摘要
基于作者最近的经验，似乎对于将系统药理学模型达到预期目的所需的步骤存在一些混淆。本文概述了作者最近在关于 5-脂氧合酶抑制剂的系统药理学研究(1)中使用的模型评估方法，并试图在药物代谢动力学和系统药理学领域内就该主题展开讨论。
相似文献
1
Evaluating systems pharmacology models is different from evaluating standard pharmacokinetic-pharmacodynamic models.评估系统药理学模型与评估标准药代动力学-药效学模型不同。
CPT Pharmacometrics Syst Pharmacol. 2014 Feb 19;3(2):e101. doi: 10.1038/psp.2013.77.
2
Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors.系统药理学模型可用于理解复杂的药代动力学-药效学行为：以 5-脂氧合酶抑制剂为例。
CPT Pharmacometrics Syst Pharmacol. 2013 Sep 11;2(9):e74. doi: 10.1038/psp.2013.49.
3
An approach for identifiability of population pharmacokinetic-pharmacodynamic models.一种群体药代动力学-药效学模型的可识别性方法。
CPT Pharmacometrics Syst Pharmacol. 2013 Jun 19;2(6):e49. doi: 10.1038/psp.2013.25.
4
CPT: Pharmacometrics and Systems Pharmacology.CPT：药物代谢动力学与系统药理学。
CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1(9):e8. doi: 10.1038/psp.2012.8.
5
An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche.临床药物研发中药代动力学和药效学原理整合的评估。罗氏公司内部经验。
Clin Pharmacokinet. 1997 Aug;33(2):142-52. doi: 10.2165/00003088-199733020-00005.
6
Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.利用效应室浓度达峰时间结合药代动力学和药效学。
Anesthesiology. 2003 Aug;99(2):324-33. doi: 10.1097/00000542-200308000-00014.
7
Pharmacometric Modeling and Simulation Is Essential to Pediatric Clinical Pharmacology.药物代谢动力学建模与模拟对儿科临床药理学至关重要。
J Clin Pharmacol. 2018 Oct;58 Suppl 10:S73-S85. doi: 10.1002/jcph.1316.
8
Advancing pharmacometrics and systems pharmacology.推进药物计量学和系统药理学。
Clin Pharmacol Ther. 2012 Nov;92(5):535-7. doi: 10.1038/clpt.2012.151.
9
Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models.Sobol 敏感性分析：指导系统药理学模型开发和评估的工具。
CPT Pharmacometrics Syst Pharmacol. 2015 Feb;4(2):69-79. doi: 10.1002/psp4.6.
10
Reproducibility of Quantitative Systems Pharmacology Models: Current Challenges and Future Opportunities.定量系统药理学模型的可重复性：当前的挑战和未来的机遇。
CPT Pharmacometrics Syst Pharmacol. 2019 Apr;8(4):205-210. doi: 10.1002/psp4.12390. Epub 2019 Mar 3.
引用本文的文献
1
An industry perspective on current QSP trends in drug development.行业视角下的药物研发中当前 QSP 趋势
J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):511-520. doi: 10.1007/s10928-024-09905-y. Epub 2024 Mar 5.
2
Towards a comprehensive assessment of QSP models: what would it take?实现 QSP 模型的全面评估：需要什么？
J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):521-531. doi: 10.1007/s10928-022-09820-0. Epub 2022 Aug 13.
3
Evaluation framework for systems models.系统模型评估框架。
CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):264-289. doi: 10.1002/psp4.12755. Epub 2022 Jan 10.
4
Where Do PBPK Models Stand in Pharmacometrics and Systems Pharmacology?生理药代动力学（PBPK）模型在药物计量学和系统药理学中处于什么地位？
CPT Pharmacometrics Syst Pharmacol. 2020 Feb;9(2):75-76. doi: 10.1002/psp4.12493. Epub 2020 Jan 26.
5
A Flexible Approach for Context-Dependent Assessment of Quantitative Systems Pharmacology Models.一种用于定量系统药理学模型上下文相关评估的灵活方法。
CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):340-343. doi: 10.1002/psp4.12409. Epub 2019 May 14.
6
Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network.最大限度地利用和重复使用定量和系统药理学模型的最佳实践：来自英国定量和系统药理学网络的建议。
CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):259-272. doi: 10.1002/psp4.12381. Epub 2019 Mar 22.
7
How Do We "Validate" a QSP Model?我们如何“验证”一个定量系统药理学（QSP）模型？
CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):547-548. doi: 10.1002/psp4.12310. Epub 2018 Aug 22.
8
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.基于生理学的药代动力学模型在监管提交中的资格认证和报告程序：联合观点。
Clin Pharmacol Ther. 2018 Jul;104(1):88-110. doi: 10.1002/cpt.1013. Epub 2018 Feb 2.
9
Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence.反向翻译在 PBPK 和 QSP 中的应用：为了更有信心地向前推进，我们需要倒序进行。
Clin Pharmacol Ther. 2018 Feb;103(2):224-232. doi: 10.1002/cpt.904. Epub 2017 Nov 9.
10
QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models.QSP 工具包：用于部署多尺度机制模型的集成工作流组件的计算实现。
AAPS J. 2017 Jul;19(4):1002-1016. doi: 10.1208/s12248-017-0100-x. Epub 2017 May 24.
本文引用的文献
1
Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors.系统药理学模型可用于理解复杂的药代动力学-药效学行为：以 5-脂氧合酶抑制剂为例。
CPT Pharmacometrics Syst Pharmacol. 2013 Sep 11;2(9):e74. doi: 10.1038/psp.2013.49.
2
Negative modeling results: a dime a dozen or a stepping stone to scientific discovery?负面建模结果：多如牛毛还是科学发现的垫脚石？
CPT Pharmacometrics Syst Pharmacol. 2013 Jun 12;2(6):e48. doi: 10.1038/psp.2013.28.
3
Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model.利用多尺度系统药理学模型预测随时间变化的骨矿物质密度的非线性变化。
CPT Pharmacometrics Syst Pharmacol. 2012 Nov 14;1(11):e14. doi: 10.1038/psp.2012.15.
4
Insulin signaling in type 2 diabetes: experimental and modeling analyses reveal mechanisms of insulin resistance in human adipocytes.2 型糖尿病中的胰岛素信号转导：实验和建模分析揭示了人脂肪细胞胰岛素抵抗的机制。
J Biol Chem. 2013 Apr 5;288(14):9867-9880. doi: 10.1074/jbc.M112.432062. Epub 2013 Feb 11.
5
Bariatric surgery and T2DM improvement mechanisms: a mathematical model.减重手术与2型糖尿病改善机制：一个数学模型
Theor Biol Med Model. 2012 May 15;9:16. doi: 10.1186/1742-4682-9-16.
6
Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.基于机制的群体模型研究维格列汀对 2 型糖尿病患者 GLP-1、血糖和胰岛素的作用。
Br J Clin Pharmacol. 2012 Mar;73(3):373-90. doi: 10.1111/j.1365-2125.2011.04109.x.
7
A hierarchical whole-body modeling approach elucidates the link between in Vitro insulin signaling and in Vivo glucose homeostasis.一种分层式全身建模方法阐明了体外胰岛素信号与体内葡萄糖动态平衡之间的联系。
J Biol Chem. 2011 Jul 22;286(29):26028-41. doi: 10.1074/jbc.M110.188987. Epub 2011 May 13.
8
Putting the pieces together in diabetes research: towards a hierarchical model of whole-body glucose homeostasis.整合糖尿病研究的各个方面：迈向全身葡萄糖稳态的层次模型。
Eur J Pharm Sci. 2009 Jan 31;36(1):91-104. doi: 10.1016/j.ejps.2008.10.027. Epub 2008 Nov 13.
Zotero 插件